Atara Biotherapeutics, Inc. (ATRA) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 16, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Atara Biotherapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Atara Biotherapeutics, Inc.'s filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Positive
CHATGPT
Turned Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Atara Biotherapeutics, Inc. actually do?
Answer:
Atara Biotherapeutics is a leader in T-cell immunotherapy, developing transformative therapies for cancer and autoimmune diseases using its allogeneic Epstein-Barr virus (EBV) T-cell platform. Its lead product, tab-cel (Ebvallo), has received marketing authorization in the European Economic Area, the United Kingdom, and Switzerland for EBV+ PTLD. The company has partnered with Pierre Fabre for worldwide commercialization of tab-cel, which is currently in Phase 3 development in the U.S. Atara has also paused development of its CAR T cell programs (ATA3219 and ATA3431) and discontinued development of ATA188 for multiple sclerosis. The company's allogeneic, off-the-shelf T-cell platform allows for rapid delivery of manufactured cells, differentiating it from autologous treatments.
Question:
What are Atara Biotherapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by commercialization agreements, including upfront fees, milestone payments, and royalties from its partner Pierre Fabre for Ebvallo (tab-cel).

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required